Acute Bacterial Skin And Skin Structure Infections Market Size, Share & Trends Analysis Report By Type of Infection, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

ABSSSI Market Size & Trends

The global acute bacterial skin and skin structure infections market size was valued at USD 1.22 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 4.84% from 2023 to 2030. The market is experiencing growth due to the increasing occurrence and recognition of acute bacterial skin and skin structure infections (ABSSSI) infections, coupled with heightened research and development efforts by pharmaceutical and biopharmaceutical companies to introduced innovative products and novel treatments in the market.

The pharmaceutical supply chain globally experienced disruptions due to the pandemic, resulting in limitations in drug availability. Despite these challenges posed by COVID-19, the global ABSSSI market is anticipated to maintain its growth trajectory. This growth is propelled by factors like the increasing incidence of bacterial skin infections in emerging countries like China, India, as well as specific regions in Latin America, the Middle East, and Africa.

Additionally, the market is expected to be propelled forward during the forecast period by the increasing activity in pipeline development and the escalating research and development investments made by pharmaceutical and biotechnology companies. Furthermore, the approval of new drugs is also projected to contribute to market growth. For instance, in 2021, according to NIH report, Ceftobiprole Medocarial, which was in Phase III trials, demonstrated its effectiveness as a treatment option for Acute bacterial skin and skin structure infections (ABSSSI) infections.

Type of Infection Insights

Based on the type of infections, acute bacterial skin and skin structure infections  market is segmented into community-acquired ABSSI and hospital- acquired ABSSI. The community- acquired ABSSI segment held the largest market share in 2022 due to their higher frequency compared to hospital-acquired infections. ABSSIs commonly occur in individuals outside healthcare settings, making them more prevalent among the general population. Additionally, the ease of transmission in community settings and the broader at-risk population contribute to the predominance of community acquired ABSSI segment in the market. On the other hand, hospital -acquired ABSSI is expected to show significant growth over the forecast period.

Route of Administration Insights

On the basis of route of administration, the market is segmented into oral, parenteral, and topical. The parenteral segment held the largest market share in 2022. ABSSSI can escalate rapidly, and parenteral antibiotics, typically delivered through intravenous (IV) or intramuscular (IM) routes, offer the advantage of rapid drug delivery, ensuring that antibiotics reach the bloodstream quickly to combat the infection effectively. On the other hand, the oral route of administration is anticipated to show lucrative growth over the forecast period.

Distribution Channel Insights

Based on distribution channel, the acute bacterial skin and skin structure infections (ABSSSI) market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment held the largest market share in 2022. Hospital pharmacies ensure timely access to critical medications and collaborate closely with healthcare teams to tailor antibiotic regimens.Additionally, hospital pharmacies facilitate a seamless transition to outpatient care by providing medications upon patient discharge, ensuring comprehensive and efficient ABSSSI treatment. On the other hand, online pharmacies are expected to show lucrative growth over the forecast period.

Regional Insights

North America dominated the market with largest market share in 2022. The significant market share in the region can be attributed to factors such as a high incidence of ABSSSI, a robust healthcare infrastructure, and substantial investments in research and development. On the other hand, Asia Pacific is expected to show significant growth over the forecast period. The region's market expansion is fueled by factors including a sizable population base and a growing awareness among individuals regarding skin health concerns.

Key Companies & Market Share Insights

Key players operating in the market are Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc.,Allergan PLC, Merck & Co., Inc, Endo Pharmaceuticals Inc., Nabriva Therapeutics PLC, Basilea Pharmaceutica Ltd, Cipher Pharmaceuticals, Menarini Group, Sandoz Inc. (Novartis), Glenmark Pharmaceuticals Ltd, and Pfizer Inc. The market participants are constantly working towards new product development, M&A activities, and other strategic alliances to gain new market avenues. The following are some instances of such initiatives:

• In May 2022, Nabriva Therapeutics PLC has completed an agreement to prolong its exclusive partnership with Merck & Co. Inc. subsidiaries for the promotion and distribution of SIVEXTRO (tedizolid phosphate) in the United States. SIVEXTRO is an antibiotic from the oxazolidinone class designed for the treatment of Acute bacterial skin and skin structure infections (ABSSSI) infections (ABSSSI). This extension will maintain the collaboration through December, 2026.